Maraldo David R. 4

What Happened David R. Maraldo, Executive Vice President and President, Merck MMD (Merck & Co., Inc.), was granted two derivative awards on May 5, 2026 totaling 29,155 restricted stock units (7,424 RSUs and 21,731 RSUs). Each line reports an acquisition at $0.00 (standard for RSU grants), so no cash changed hands at grant.

Key Details

• Transaction date: 2026-05-05; Form 4 filed: 2026-05-07 (appears timely).
• Awards: 7,424 RSUs (0.00 price) and 21,731 RSUs (0.00 price); total = 29,155 RSUs.
• Shares owned after transaction: not specified in the filing.
• Footnotes from the filing:
  • F1: Each restricted stock unit represents a contingent right to receive one share of Merck common stock.
  • F2: These RSUs vest and will be distributed as shares in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029.
  • F3: Notes an option vesting schedule (vests in equal installments on 5/5/2027, 5/5/2028, and 5/5/2029) as referenced in the filing.
• Transaction code: A = Award/Grant (derivative).

Context These are restricted stock unit grants (not open-market purchases or sales). RSUs are a form of compensation that convert to common shares only after they vest (per F2), so they are not immediately marketable. Because this is a grant (no cash outlay or share sale), it should be read as compensation-related rather than a direct bullish or bearish signal from insider buying/selling.